Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quizartinib plus standard chemotherapy vs placebo in newly diagnosed FLT3 wild-type AML
2018-002851-14Phase 2Active
- Sponsor
- PETHEMA
- Start
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in acute myeloid leukemia (AML) comparing Quizartinib + standard chemotherapy with Placebo + standard chemotherapy (2 arms). Primary endpoint: Event-free survival. Started Jun 2019; status: active.
02
Drugs
quizartinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2018-002851-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002851-14.